Project A Phase 1B Multicenter,Open-labelStudy to determine the recommended dose and Regimen of…
Basic data
Title:
A Phase 1B Multicenter,Open-labelStudy to determine the recommended dose and Regimen of Durvalumab(MEDI4736)ceither as Monotherapy or in combination with Pomalidomide(Pom) with or without Low-dose Dexamethasone(Dex) in subjects with relapsed and refractory Multiple Myeloma(RRMM).
Duration:
10/05/2016 to 01/06/2017
Abstract / short description:
A Phase 1B Multicenter,Open-labelStudy to determine the recommended dose and Regimen of Durvalumab(MEDI4736)ceither as Monotherapy or in combination with Pomalidomide(Pom) with or without Low-dose Dexamethasone(Dex) in subjects with relapsed and refractory Multiple Myeloma(RRMM).
Keywords:
Durvalumab
Multiples Myelom
Involved staff
Managers
Faculty of Medicine
University of Tübingen
University of Tübingen
Contact persons
Faculty of Medicine
University of Tübingen
University of Tübingen
Local organizational units
Internal Medicine Department II
Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Boudry, Switzerland